- Going to BPI West 2017? Don’t miss these great talks and activities!Posted 1 day ago
- Cool Tool – PRIME-XV® T Cell CDM – First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 4 days ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 1 week ago
- Continuous Processing Optimization with Smarter ToolsPosted 1 week ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 2 weeks ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 2 weeks ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 3 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
The Dish’s Weekly News Wrap Up – April 27, 2012
This is a new feature where we will highlight some of the week’s top biotechnology stories.
US biopharmaceutical companies are developing nearly 300 vaccines for the prevention and treatment of a wide variety of diseases, according to new industry data.
Stay tuned for an upcoming vaccine production series on The Dish
A $30 million effort from California’s stem cell research funding agency will dole out awards to help biotech or pharmaceutical companies or venture capital firms take research into early clinical trials.
If you like this story, please see our stem cell blog titled “Exciting Treatment Possibilities With Stem Cells What is the Best Cell Culture Method”
Drug companies are in such need of the latest experimental therapies to replace medicines losing patent protection that even a 68 percent takeover premium for Human Genome Sciences Inc. isn’t enough.
If you like this story, please see our blog titled “CHO Cells the Top Expression System of Best Selling Biologic Drugs”
George B. Rathmann, who was the first chief executive of Amgen and helped build it into the world’s largest biotechnology company, died on Sunday at his home in Palo Alto, Calif. He was 84.
In hundreds of documented cases that undermine a broad swath of research, cancer samples that were supposed to be one type of tumor have turned out to be another, through either careless laboratory handling, mislabeling or other mistakes.
If you like this story, please see our blog titled “Has Your Research Been Compromised? The Role of Cell-Line Authentication”